Explore the Agenda
7:30 am Check-In & Morning Coffee
8:20 am Chair’s Opening Remarks
Navigating the Evolving TPD Landscape to Understand Future Directions & Drive the Next-Generation of Proximity Therapeutics
8:30 am Panel Discussion: The TPD Investment Landscape: Lessons from Deals in 2025 & Expectations for 2026
9:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing
9:45 am Illuminating New Insights in Targeted Protein Degradation Kinetics, Mechanisms, & Selectivity
10:15 am Expanding Targeted Glue Applications by Recruiting Novel E3 Ligases Across Diverse Targets
10:45 am Morning Break & Networking
Track A: Discovery
Accelerating Molecular Glue Innovation Through Structure-Guided Design & Empirical Discovery to Enable Selective Targeting & Unlock New Therapeutic Opportunities
11:30 am Structure-Based Development of Non-Degrader Molecular Glues to Selectively Stabilize a Tumor Suppressor Phosphatase Complex
Head of Structural Biology (Rappta Therapeutics); Professor (Case Western Reserve University), Case Western Reserve University
12:00 pm Session Reserved for LifeSensors Inc
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
12:30 pm Lunch Break & Networking
Track A: Discovery
Advancing Integrase Degraders & Decoding Cooperativity in Induced Proximity to Overcome Enable Potent, Orally Bioavailable & Safe Therapeutics
1:30 pm Developing an HIV Integrase Degrader to Unlock the Infectious Indication Landscape for Degraders
Chief Executive Officer, EndoTarget
2:00 pm Panel Discussion: Cracking the Code: Understanding & Measuring Cooperativity in Induced Proximity Modalities
Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals
Director - Biophysics, High Throughput Screening & Oncology, Pfizer
Executive Director - Discovery Science, Revolution Medicines
CEO, TenAces Biosciences
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development